We are live on ! Find out more
PVI

Pura Vida Investments Portfolio holdings

AUM $14.9M
1-Year Est. Return 38.76%
This Fund
S&P 500
This Quarter Est. Return
-11.04%
1 Year Est. Return
+38.76%
3 Year Est. Return
+26.8%
5 Year Est. Return
+25.03%
10 Year Est. Return
+1,723.84%
AUM
$175M
AUM Growth
-$20.2M
Cap. Flow
+$10.1M
Cap. Flow %
5.76%
Top 10 Hldgs %
36.8%
Holding
85
New
16
Increased
25
Reduced
11
Closed
19

Top Buys

Rank Stock Value
1
ABT icon
Abbott
ABT
+$3.77M
2
VAR
Varian Medical Systems, Inc.
VAR
+$3.33M
3
BSX icon
Boston Scientific
BSX
+$3.08M
4
ELGX
Endologix Inc
ELGX
+$2.78M
5
BXLT
BAXALTA INC COM STK (DE)
BXLT
+$2.76M

Top Sells

Rank Stock Value
1
SIEN
Sientra, Inc.
SIEN
+$5.61M
2
ALIM
Alimera Sciences
ALIM
+$4.5M
3
SPNC
Spectranetics Corp
SPNC
+$4.48M
4
COO icon
Cooper Companies
COO
+$4.42M
5
CPHD
Cepheid Inc
CPHD
+$3.33M

Sector Composition

Rank Sector Weight
1 Healthcare 65.75%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALIM
26
CALL
DELISTED
Alimera Sciences
ALIM
$2.76M 1.58%
+83,333
New +$4.69M
PRGO icon
27
Perrigo
PRGO
$1.76B
$2.75M 1.57%
17,500
+375
+2% +$68.8K
KITE
28
DELISTED
Kite Pharma, Inc.
KITE
$2.71M 1.55%
48,750
+12,750
+35% +$802K
BXLT
29
DELISTED
BAXALTA INC COM STK (DE)
BXLT
$2.52M 1.44%
+80,000
New +$2.76M
ELGX
30
DELISTED
Endologix Inc
ELGX
$2.52M 1.44%
+20,510
New +$2.78M
EW icon
31
Edwards Lifesciences
EW
$53.6B
$2.49M 1.42%
105,000
-45,000
-30% -$1.09M
JAZZ icon
32
Jazz Pharmaceuticals
JAZZ
$16.3B
$2.39M 1.36%
18,000
– –
AFFX
33
DELISTED
Affymetrix Inc
AFFX
$2.39M 1.36%
280,000
-20,000
-7% -$200K
ACH
34
Accendra Health
ACH
$94.2M
$2.24M 1.28%
70,000
-35,000
-33% -$1.19M
QGENF
35
DELISTED
QIAGEN NV
QGENF
$2.19M 1.25%
85,000
-15,000
-15% -$387K
SGYP
36
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
$2.12M 1.21%
400,000
+153,750
+62% +$1.19M
ALXN
37
DELISTED
Alexion Pharmaceuticals
ALXN
$1.96M 1.12%
12,500
– –
SNN icon
38
Smith & Nephew
SNN
$12.6B
$1.93M 1.1%
55,000
-50,000
-48% -$1.78M
AGN
39
DELISTED
Allergan plc
AGN
$1.9M 1.09%
+7,000
New +$2.15M
BCR
40
DELISTED
CR Bard Inc.
BCR
$1.86M 1.06%
+10,000
New +$1.89M
ASXC
41
DELISTED
Asensus Surgical, Inc.
ASXC
$1.83M 1.05%
62,339
+3,724
+6% +$138K
EWA icon
42
PUT
iShares MSCI Australia ETF
EWA
$1.47B
$1.79M 1.02%
+100,000
New +$1.96M
ADYX
43
DELISTED
Adynxx Inc
ADYX
$1.66M 0.95%
8,717
+1,717
+25% +$481K
ZLTQ
44
DELISTED
ZELTIQ Aesthetics, Inc.
ZLTQ
$1.6M 0.91%
+50,000
New +$1.66M
AKRX
45
DELISTED
Akorn Inc
AKRX
$1.43M 0.82%
50,200
+3,325
+7% +$137K
SAGE
46
DELISTED
Sage Therapeutics
SAGE
$1.19M 0.68%
28,000
– –
TNXP icon
47
Tonix Pharmaceuticals
TNXP
$195M
– –
0
– –
PEN icon
48
Penumbra
PEN
$12.8B
$1.03M 0.59%
+25,800
New +$1.04M
DCOY
49
Decoy Therapeutics
DCOY
$2.03M
– –
0
– –
ZGNX
50
DELISTED
Zogenix, Inc.
ZGNX
$793K 0.45%
58,750
+52,422
+828% +$946K
1
2
3 4

Similar funds

BCA
Boundary Creek Advisors New York $15.3M AUM 0.41% 1-Year Est. Return
RC
Raine Capital New York $14.1M AUM 33.16% 1-Year Est. Return
DOFI
DCVC Opportunity Fund II Palo Alto, California $13.9M AUM 8.04% 1-Year Est. Return
SCI
SkyBridge Capital II New York $13.1M AUM 3.36% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
GBCP
Glade Brook Capital Partners Greenwich, Connecticut $12.8M AUM
SCTC
Samsung C&T Corporation Seoul, South Korea $17.2M AUM 23.45% 1-Year Est. Return
M
MetLife New York $12.3M AUM 29% 1-Year Est. Return

Pura Vida Investments's Q3 2015 Portfolio in Review

As of Q3 2015, Pura Vida Investments held 85 positions worth $175M, down 10% from $195M the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Pura Vida Investments deployed $10.1M of net new capital in Q3 2015, opening 16 new positions and adding to 25 existing holdings. Its largest new stake was Abbott: 80,000 shares worth $3.22M.

By sector, the portfolio is most concentrated in Healthcare at 66% of assets, down from 70% a quarter earlier.

On the sell side, the largest reduction was Alimera Sciences, an estimated $4.5M trimmed.

  • Pura Vida Investments's largest Q3 2015 buy was Abbott: 80,000 shares worth $3.22M.
  • Pura Vida Investments added most to Boston Scientific in Q3 2015, an estimated $3.08M increase.
  • Pura Vida Investments's biggest Q3 2015 reduction was Alimera Sciences, cutting an estimated $4.5M.
  • Pura Vida Investments fully exited Sientra, Inc. in Q3 2015, selling an estimated $5.61M.
  • Pura Vida Investments's ten largest holdings make up 37% of its $175M portfolio in Q3 2015.
  • Pura Vida Investments opened 16 new positions and closed 19 in Q3 2015.
  • Pura Vida Investments's portfolio value fell 10% quarter-over-quarter to $175M.

Based on Pura Vida Investments's 13F filing for Q3 2015, filed 16 Nov 2015.